Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate Cancer
Abstract
The antifungal drug itraconazole inhibits angiogenesis and Hedgehog signaling and delays tumor growth in murine prostate cancer xenograft models. We conducted a noncomparative, randomized, phase II study evaluating the antitumor efficacy of two doses of oral itraconazole in men with metastatic prostate cancer.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 22, 2013
- Source ID
- 10.1634/theoncologist.2012-314
Entities
People
- A. Seun Ajiboye
- Amanda L. Blackford
- Anja Frost
- Dana Rathkopf
- Daniel C. Danila
- David C. Smith
- Elisabeth I Heath
- Emmanuel S. Antonarakis
- Janet Mendonca
- Michael A. Carducci
- Michelle A. Rudek
- Ming Zhao
- Serina King
- Sushant K. Kachhap
Organizations
- National Center for Research Resources
- National Institutes of Health
- United States Department of Defense
- University of Michigan
- Wayne State University